A new study from UCLA reveals that creatine, a supplement widely used in fitness circles, could enhance the effectiveness of cancer immunotherapy by supporting the immune system’s dendritic cells—key players in training killer T cells to fight tumors.
- Creatine fuels dendritic cells that activate cancer-fighting T cells.
- Supplementing creatine in mice slowed tumor growth significantly.
- Could improve dendritic cell vaccines used in immunotherapy.
What happened
Scientists at UCLA investigated why many cancer patients do not respond to immunotherapy, focusing beyond the killer T cells to the dendritic cells that activate them. By analyzing tumor-infiltrating dendritic cells in mice, the research team noticed heightened activity of the gene responsible for the creatine transporter. This hinted that creatine was an important energy source for these immune cells.
To test this, they removed the creatine transporter from dendritic cells, which led to poorer survival and reduced activation of these cells. Conversely, mice given daily creatine injections showed slower tumor growth and an increase in active dendritic cells within tumors. The study also demonstrated that creatine helped raise intracellular ATP levels, boosting the immune cells’ energy and function.
Why it feels good
This discovery shines a hopeful light on a natural supplement already familiar and considered safe by many. Creatine’s ability to power the immune system’s supporting cells suggests a new way to enhance cancer immunotherapy more holistically, rather than focusing solely on the T cells themselves.
Research showed that besides benefiting mice, creatine also improved the function of human dendritic cells in lab tests. These cells are often used to create dendritic cell vaccines, hinting at a future where creatine could help boost the potency of these treatments before they reach patients. The potential to complement existing therapies with an accessible supplement feels like a positive step forward.
What to enjoy or watch next
While these findings come from mouse models and laboratory studies, the next exciting phase will be clinical trials that test creatine supplementation in actual cancer patients undergoing immunotherapy. Researchers intend to explore creatine both as a direct supplement during treatment and as part of improving dendritic cell-based vaccines.
If proven effective in humans, creatine could become a low-barrier addition to cancer treatment plans, possibly increasing response rates and providing fresh hope to the many patients currently without effective options. Until then, patients should consult their doctors before considering creatine, as research continues to unfold.